China Pharma Holdings Reports Decline in Revenue and Increased Operating Loss in Q2 2026

China Pharma Holdings, Inc. reported a decline in financial performance for the second quarter of 2026, with revenues of $948,340, down from $1,025,767 in the same period of 2025. For the first half of 2026, total revenue was $1,931,876, a decrease of 10.6% compared to $2,162,054 in the first half of 2025. The company attributed this decline primarily to increased competition and the exclusion of some of its products from the national centralized procurement program, which has affected sales of its anti-viral and respiratory products.

The company's gross profit for the second quarter was $83,566, a significant improvement from a gross loss of $87,010 in the prior year. This shift to profitability was driven by reduced costs associated with the depreciation of property, plant, and equipment. However, operating expenses surged to $1,515,411 for the quarter, up from $565,110 in the same period last year, largely due to increased general and administrative expenses related to the acquisition of new patented technologies. Consequently, the operating loss widened to $1,431,845, compared to a loss of $652,120 in the second quarter of 2025.

In terms of operational metrics, the company reported a net loss of $1,458,123 for the second quarter, compared to a net loss of $528,367 in the same quarter of 2025. The loss per share was $0.04, a decrease from $0.16 in the previous year. The weighted average shares outstanding increased significantly to 40,522,002 from 3,226,156, reflecting the issuance of new shares for acquisitions. The company’s total assets rose to $44.71 million as of June 30, 2026, up from $31.00 million at the end of 2025, primarily due to the increase in intangible assets following the acquisition of new technologies.

China Pharma's strategic developments included the acquisition of five new patented technologies, which contributed to higher amortization expenses. The company also entered into a securities purchase agreement on July 22, 2026, to sell 2,500,000 shares at $2.00 per share, expected to generate approximately $4.43 million in net proceeds to support operational cash flow. Despite the challenges faced, the company aims to optimize its product portfolio, particularly focusing on the cardiovascular and cerebrovascular sectors, to enhance profitability and operational resilience moving forward.

Looking ahead, China Pharma plans to continue its efforts in the consistency evaluation of its products and adapt to the evolving pharmaceutical landscape in China. The company remains cautious about market conditions and competition, particularly in the anti-viral and respiratory segments, while leveraging its strengths in the CNS and cardiovascular markets to drive future growth.